Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical


You May Also Like

Retrophin Appoints Roy D. Baynes, M.D., Ph.D., to Board of Directors

SAN DIEGO, July 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment ...

Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), ...